Skip Navigation
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Internet Explorer is no longer a supported browser.

This website may not display properly with Internet Explorer. For the best experience, please use a more recent browser such as the latest versions of Google Chrome, Microsoft Edge, and/or Mozilla Firefox. Thank you.

COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC. Get the latest research information from NIH.

Your Environment. Your Health.

Person Details: Joseph R. Testa

Superfund Research Program

Joseph R. Testa

Fox Chase Cancer Center
333 Cottman Avenue
Office P3037
Philadelphia, Pennsylvania 19111-2467
Phone: 215-728-2610
Fax: 215-214-1623
Email: joseph.testa@fccc.edu

Projects

Patents

Publications

2017

  • Cheung M, Menges CW, Testa JR. 2017. Germline and Somatic Mutations in Human Mesothelioma and Lessons from Asbestos-Exposed Genetically Engineered Mouse Models. Chapter 8 in: Asbestos and Mesothelioma. Springer International Publishing, pp.175-195.
  • Cheung M, Testa JR. 2017. BAP1, a tumor suppressor gene driving malignant mesothelioma. Transl Lung Cancer Res 6(3):270-278. doi:10.21037/tlcr.2017.05.03 PMID:28713672 PMCID:PMC5504107
  • Testa JR. 2017. Malignant Mesothelioma: An Asbestos Legacy. Chapter 1 in: Asbestos and Mesothelioma. Springer International Publishing, pp.1-9.

2016

  • Kadariya Y, Cheung M, Xu J, Pei J, Sementino E, Menges CW, Cai KQ, Rauscher FJ, Klein-Szanto AJ, Testa JR. 2016. Bap1 is a bona fide tumor suppressor: genetic evidence from mouse models carrying heterozygous germline Bap1 mutations. Cancer Res 76(9):2836-2844. doi:10.1158/0008-5472.CAN-15-3371 PMID:26896281 PMCID:PMC4873414
  • Kadariya Y, Menges CW, Talarchek J, Cai KQ, Klein-Szanto AJ, Pietrofesa RA, Christofidou-Solomidou M, Cheung M, Mossman BT, Shukla A, Testa JR. 2016. Inflammation-related IL1β/IL1R signaling promotes the development of asbestos-induced malignant mesothelioma. Cancer Prev Res (Phila) 9(5):406-414. doi:10.1158/1940-6207.CAPR-15-0347 PMID:26935421 PMCID:PMC4854753
  • Ohar J, Cheung M, Talarchek J, Howard S, Howard T, Hesdorffer M, Peng H, Rauscher FJ, Testa JR. 2016. Germline BAP1 mutational landscape of asbestos-exposed malignant mesothelioma patients with family history of cancer. Cancer Res 76(2):206-215. doi:10.1158/0008-5472.CAN-15-0295 PMID:26719535 PMCID:PMC4715907
  • Pietrofesa RA, Velalopoulou A, Arguiri E, Menges CW, Testa JR, Hwang W, Albelda SM, Christofidou-Solomidou M. 2016. Flaxseed lignans enriched in secoisolariciresinol diglucoside prevent acute asbestos-induced peritoneal inflammation in mice. Carcinogenesis 37(2):177-187. doi:10.1093/carcin/bgv174 PMID:26678224 PMCID:PMC4745643

2015

  • Cheung M, Kadariya Y, Pei J, Talarchek J, Facciolo F, Visca P, Righi L, Cozzi I, Testa JR, Ascoli V. 2015. An asbestos-exposed family with multiple cases of pleural malignant mesothelioma without inheritance of a predisposing BAP1 mutation. Cancer Genet 208(10):502-507. doi:10.1016/j.cancergen.2015.07.004 PMID:26364129 PMCID:PMC4608746
  • Cheung M, Kadariya Y, Talarchek J, Pei J, Ohar J, Kayaleh O, Testa JR. 2015. Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction. Cancer Lett 369(2):261-265. doi:10.1016/j.canlet.2015.09.011 PMID:26409435 PMCID:PMC4634709
  • Karla N, Zhang J, Thomas A, Xi L, Talarchek J, Burkett S, Tsokos MG, Chen Y, Raffeld M, Miettinen M, Pastan I, Testa JR, Hassan R, Cheung M. 2015. Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma. BMC Cancer 15:376. doi:10.1186/s12885-015-1362-2 PMID:25952750 PMCID:PMC4431029
Back
to Top